Can You Survive Lung Cancer? Real Survival Rates by Stage

Stage 4 lung cancer corresponds most closely to the distant SEER category. The current ACS 5-year relative survival rates for distant-stage disease: 12% for NSCLC and 4% for SCLC. These figures are population averages from patients diagnosed 2015-2021. They do not reflect current standard-of-care use of targeted therapy and immunotherapy, which has improved outcomes in advanced NSCLC and extensive-stage SCLC. They are also not a prediction for any one person. Ask your oncology team what your specific molecular profile and treatment plan mean for your individual outlook.

Yes, early-stage lung cancer can often be treated with curative intent18. For localised NSCLC (roughly stage 1 and some stage 2), the current ACS 5-year relative survival rate is 67%. For many patients, the goal is cure through surgery, sometimes with adjuvant therapy. For localised SCLC, the 5-year relative survival is 34%. Limited-stage SCLC is where cure or long-term remission is realistic with combined chemotherapy and radiation. The earlier the stage, the more treatment options, which is why timely investigation of persistent symptoms matters.

Mostly no, with a time lag. Published 5-year survival statistics are drawn from cohorts of patients diagnosed years earlier. The current ACS NSCLC data comes from patients diagnosed between 2015 and 2021. Treatment has advanced greatly in that time. Expanded use of targeted therapies matched to specific driver mutations and immune checkpoint inhibitors (immunotherapy) has changed what is possible. Especially for NSCLC with actionable mutations and for extensive-stage SCLC. In practical terms, current outcomes for a patient diagnosed today are likely better than the published figures suggest. This is mainly true for NSCLC with an actionable driver mutation identified through comprehensive molecular testing.

Overall, NSCLC has a more favourable outlook than SCLC across every SEER stage. NSCLC 5-year relative survival is higher at each stage: localised 67% vs 34%, regional 40% vs 20%, distant 12% vs 4%. SCLC grows and spreads more rapidly, and most cases are already extensive-stage by diagnosis6. However, SCLC often responds strongly to chemotherapy and radiation in the first line of treatment. The recent addition of immunotherapy to the standard-of-care regimen has improved outcomes in extensive-stage SCLC. Stage at diagnosis matters more than type for most patients when considering individual outlook.